Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Opthea ( (AU:OPT) ) has issued an announcement.
Opthea reported a sharp turnaround in its half-year results to 31 December 2025, posting profit after tax attributable to owners of A$339.9 million, a 269% increase on the prior corresponding period. Net tangible assets per ordinary share also swung into positive territory at 2.46 cents, compared with a negative 24.93 cents a year earlier, while the board maintained its policy of not declaring dividends as it continues to focus resources on advancing the business.
The company reported no changes in control over entities, no associates or joint ventures, and confirmed that its half-year financial statements have been reviewed by auditors. The stronger balance sheet and return to profitability may enhance Opthea’s financial flexibility and support its strategic positioning in the competitive biotech sector, even as it opts to reinvest rather than distribute cash to shareholders.
The most recent analyst rating on (AU:OPT) stock is a Sell with a A$0.56 price target. To see the full list of analyst forecasts on Opthea stock, see the AU:OPT Stock Forecast page.
More about Opthea
Opthea Limited is an Australian biotechnology company focused on developing therapies for eye diseases, particularly retinal conditions. The company operates internationally through subsidiaries such as Opthea US Inc, reporting under International Financial Reporting Standards and targeting global ophthalmology markets.
Technical Sentiment Signal: Sell
Current Market Cap: A$738.8M
See more data about OPT stock on TipRanks’ Stock Analysis page.